Aim immunotech enrolls and doses first subject in phase 2 study evaluating ampligen® for the treatment of post-covid conditions

Preliminary ampligen data demonstrates potential to be an effective treatment option for post-covid conditions enrollment expected to be completed in q4 2023 ocala, fla., july 10, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim”) today announced it has enrolled and dosed the first subject in the company's phase 2 study evaluating ampligen® as a potential therapeutic for people with post-covid conditions (“amp-518”).
AIM Ratings Summary
AIM Quant Ranking